Paliperidone: all 134 studies that test it

Page 2 of 2. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With SchizophreniaCompletedNCT00915512Phase 4
• A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS PaliperidoneCompletedNCT00892541Phase 1
• A Bioequivalence Study of 15 mg ER OROS PaliperidoneCompletedNCT00892489Phase 1
• A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese VolunteersCompletedNCT00892320Phase 1
• Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With SchizophreniaCompletedNCT00827840Phase 4
• A Dose-proportionality Study of Five Tablet Strengths of ER OROS PaliperidoneCompletedNCT00796835Phase 1
• A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release FormulationsCompletedNCT00796471Phase 1
• As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release FormulationsCompletedNCT00796185Phase 1
• A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ERCompletedNCT00791713Phase 1
• A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or QuetiapineCompletedNCT00791622Phase 1
• A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal FunctionCompletedNCT00791401Phase 1
• A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IRCompletedNCT00791193Phase 1
• A Study of the Dose Proportionality of Extended Release PaliperidoneCompletedNCT00791167Phase 1
• A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and VacavilleCompletedNCT00790777Phase 1
• Effects of Paliperidone in Posttraumatic Stress Disorder (PTSD)WithdrawnNCT00766064Phase 4
• A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.CompletedNCT00668837Phase 3
• An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With SchizophreniaCompletedNCT00460512Phase 3
• A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I DisorderCompletedNCT00309699Phase 3
• A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I DisorderCompletedNCT00309686Phase 3
• A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I DisorderCompletedNCT00299715Phase 3
• An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With SchizophreniaCompletedNCT00257023Phase 2
• A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With SchizophreniaCompletedNCT00210717Phase 3
• A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With SchizophreniaCompletedNCT00210548Phase 3
• A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With SchizophreniaCompletedNCT00119756Phase 3
• A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.CompletedNCT00111189Phase 3
• Trial Evaluating Paliperidone Extended-Release (ER) Tablets Versus Placebo on Sleep in Schizophrenia PatientsCompletedNCT00105326Phase 2
• Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With SchizophreniaCompletedNCT00101634Phase 3
• A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.CompletedNCT00086320Phase 3
• Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With SchizophreniaCompletedNCT00085748Phase 3
• Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With SchizophreniaCompletedNCT00083668Phase 3
• Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With SchizophreniaCompletedNCT00078039Phase 3
• Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With SchizophreniaCompletedNCT00077714Phase 3
• Safety and Efficacy of an Anti-Psychotic in Patients With SchizophreniaCompletedNCT00074477Phase 2
• Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With SchizophreniaCompletedNCT00073320Phase 3

← Paliperidone overview